Doron Lancet's work has been supported for 20 years by the Weizmann Crown Human Genome Center, and by a grant from LifeMap Sciences Inc., California, USA. It is also currently supported by an NIH grant DC000298-17, the PIONEER European Network of Excellence for Big Data in Prostate Cancer, the DC-ren Horizon 2020 EU grant on Drug combinations for rewriting trajectories of renal pathologies in type II diabetes and by a Minerva Center for Life Under Extreme Planetary Conditions.